MedTrace Logo

Biweekly Avastin and Docetaxel as the First Line Treatment for Patients With Metastatic Breast Cancer

NCT00979641 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2019-03-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of the combination of biweekly docetaxel and bevacizumab in the first line treatment of metastatic breast cancer by using Response Evaluation Criteria In Solid Tumors (RECIST criteria) and NCI Common Terminology Criteria for Adverse Events (NCI CTC-AE) version 3. In addition several biochemical makers are tested as possible predictive factors.

Conditions

  • Neoplasms

Interventions

DRUG

Docetaxel

Sponsors & Collaborators

  • Oulu University Hospital

    collaborator OTHER

  • Turku University Hospital

    collaborator OTHER_GOV

  • Tampere University Hospital

    lead OTHER

Principal Investigators

  • Pirkko-Liisa I Kellokumpu-Lehtinen, MD · Tampere University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00979641 on ClinicalTrials.gov